FDA Panel Rejects OTC Cholesterol Drug
Experts Recommend That Mevacor Remain a Prescription Drug
Label Education continued...
Panel member Robert E. Taylor, MD, said Mevacor should be sold without a
prescription despite evidence that many consumers won't use it correctly.
"I think we've got a major problem with this elevated cholesterol, and
I'm willing to take a chance," said Taylor, chairman of the department of
pharmacology at the Howard University School of Medicine in Washington,
But many other panelists said there were too many potential pitfalls in
selling Mevacor over the counter. Patients may not accurately identify that the
drug is right for them. Once they do, they may not use it correctly. If they
use it correctly, they may not use it correctly for long enough. And if they
use if for long enough, they could avoid seeing a doctor because of a belief
that they were already being treated.
Merck tried to address each of these pitfalls by including a large amount of
patient information in its packaging. It included three separate brochures,
along with safety information on the outside of the box.
Tinetti, the panel's chairwoman, said she became confused while reviewing
the information with Merck officials.
"I'm just thinking of how long it would actually take [to read it]. And
then you lose, I lose, my train of thought in this," she said.